ZA201406148B - Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof - Google Patents
Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereofInfo
- Publication number
- ZA201406148B ZA201406148B ZA2014/06148A ZA201406148A ZA201406148B ZA 201406148 B ZA201406148 B ZA 201406148B ZA 2014/06148 A ZA2014/06148 A ZA 2014/06148A ZA 201406148 A ZA201406148 A ZA 201406148A ZA 201406148 B ZA201406148 B ZA 201406148B
- Authority
- ZA
- South Africa
- Prior art keywords
- imidazo
- pyridazine
- compositions
- based compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608758P | 2012-03-09 | 2012-03-09 | |
| PCT/US2013/029043 WO2013134219A1 (en) | 2012-03-09 | 2013-03-05 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201406148B true ZA201406148B (en) | 2016-06-29 |
Family
ID=48014284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/06148A ZA201406148B (en) | 2012-03-09 | 2014-08-21 | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8969565B2 (OSRAM) |
| EP (1) | EP2822559B1 (OSRAM) |
| JP (1) | JP6418949B2 (OSRAM) |
| KR (1) | KR102085121B1 (OSRAM) |
| CN (1) | CN104470523B (OSRAM) |
| AR (1) | AR090291A1 (OSRAM) |
| AU (1) | AU2013230119B2 (OSRAM) |
| BR (1) | BR112014022271B1 (OSRAM) |
| CA (1) | CA2866164C (OSRAM) |
| ES (1) | ES2676826T3 (OSRAM) |
| IL (1) | IL234485A (OSRAM) |
| MX (1) | MX347917B (OSRAM) |
| NZ (1) | NZ630719A (OSRAM) |
| RU (1) | RU2014140739A (OSRAM) |
| SG (1) | SG11201405563VA (OSRAM) |
| TW (1) | TW201341385A (OSRAM) |
| UY (1) | UY34669A (OSRAM) |
| WO (1) | WO2013134219A1 (OSRAM) |
| ZA (1) | ZA201406148B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| JP6105578B2 (ja) | 2011-07-21 | 2017-03-29 | トレロ ファーマシューティカルズ， インコーポレイテッド | 複素環式プロテインキナーゼ阻害剤 |
| IN2014DN07384A (OSRAM) | 2012-03-09 | 2015-04-24 | Lexicon Pharmaceuticals Inc | |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| EP3054955B1 (en) | 2013-10-11 | 2018-05-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2015089143A1 (en) * | 2013-12-10 | 2015-06-18 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| LT3636649T (lt) * | 2014-01-24 | 2024-04-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklai kaip proteinkinazių moduliatoriai |
| JP6441947B2 (ja) * | 2014-01-31 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キノリンを基にしたキナーゼ阻害剤 |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| US20170239249A1 (en) * | 2014-09-30 | 2017-08-24 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| PT3215511T (pt) | 2014-11-06 | 2024-05-22 | Bial R&D Invest S A | Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos |
| WO2016164295A2 (en) | 2015-04-10 | 2016-10-13 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| SMT202400213T1 (it) * | 2015-07-06 | 2024-07-09 | Turning Point Therapeutics Inc | Polimorfo di diaril macrociclo |
| ES2818528T3 (es) | 2015-07-21 | 2021-04-13 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer |
| ES2828733T3 (es) * | 2015-11-18 | 2021-05-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| EP3440080A4 (en) | 2016-04-06 | 2020-01-22 | Lysosomal Therapeutics Inc. | PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| EP4285996A3 (en) * | 2016-04-15 | 2024-01-10 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| EP4101853A1 (en) * | 2017-03-14 | 2022-12-14 | Daiichi Sankyo Company, Limited | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative |
| CN107082828B (zh) * | 2017-05-19 | 2019-09-17 | 暨南大学 | 一种活性氧响应性高分子载体及其制备方法 |
| EP3658148B1 (en) | 2017-07-28 | 2024-07-10 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| US10899733B2 (en) | 2017-08-23 | 2021-01-26 | Oregon Health & Science University | Inhibitors of PARPs that catalyze mono-ADP-ribosylation |
| MX2020006490A (es) | 2017-12-19 | 2020-08-17 | Turning Point Therapeutics Inc | Compuestos macrociclicos para tratar enfermedades. |
| JP7662528B2 (ja) | 2019-02-12 | 2025-04-15 | スミトモ ファーマ アメリカ， インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
| CN110684028B (zh) * | 2019-10-28 | 2021-10-26 | 上海阿拉丁生化科技股份有限公司 | 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法 |
| WO2021216757A1 (en) * | 2020-04-21 | 2021-10-28 | The Uab Research Foundation | Rna-binding protein multimerization inhibitors and methods of use thereof |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| CN117120090A (zh) * | 2021-02-12 | 2023-11-24 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO2007025090A2 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7750000B2 (en) * | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2663091A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| WO2008052734A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| FR2934994B1 (fr) * | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| US8450322B2 (en) * | 2008-09-22 | 2013-05-28 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors |
| IN2014DN07384A (OSRAM) | 2012-03-09 | 2015-04-24 | Lexicon Pharmaceuticals Inc | |
| HK1199814A1 (en) | 2012-03-09 | 2015-07-24 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
-
2013
- 2013-03-05 CA CA2866164A patent/CA2866164C/en active Active
- 2013-03-05 MX MX2014010584A patent/MX347917B/es active IP Right Grant
- 2013-03-05 SG SG11201405563VA patent/SG11201405563VA/en unknown
- 2013-03-05 RU RU2014140739A patent/RU2014140739A/ru not_active Application Discontinuation
- 2013-03-05 ES ES13712953.2T patent/ES2676826T3/es active Active
- 2013-03-05 WO PCT/US2013/029043 patent/WO2013134219A1/en not_active Ceased
- 2013-03-05 KR KR1020147028073A patent/KR102085121B1/ko active Active
- 2013-03-05 JP JP2014561020A patent/JP6418949B2/ja active Active
- 2013-03-05 NZ NZ630719A patent/NZ630719A/en unknown
- 2013-03-05 EP EP13712953.2A patent/EP2822559B1/en active Active
- 2013-03-05 US US13/785,271 patent/US8969565B2/en active Active
- 2013-03-05 AU AU2013230119A patent/AU2013230119B2/en active Active
- 2013-03-05 BR BR112014022271-1A patent/BR112014022271B1/pt active IP Right Grant
- 2013-03-05 CN CN201380021272.3A patent/CN104470523B/zh active Active
- 2013-03-08 TW TW102108279A patent/TW201341385A/zh unknown
- 2013-03-11 UY UY0001034669A patent/UY34669A/es not_active Application Discontinuation
- 2013-03-11 AR ARP130100764A patent/AR090291A1/es unknown
-
2014
- 2014-08-21 ZA ZA2014/06148A patent/ZA201406148B/en unknown
- 2014-09-07 IL IL234485A patent/IL234485A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,097 patent/US20160024093A1/en not_active Abandoned
-
2016
- 2016-04-26 US US15/138,460 patent/US20170057964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014140739A (ru) | 2016-04-27 |
| US20130245021A1 (en) | 2013-09-19 |
| JP6418949B2 (ja) | 2018-11-07 |
| ES2676826T3 (es) | 2018-07-25 |
| HK1203407A1 (en) | 2015-10-30 |
| CA2866164A1 (en) | 2013-09-12 |
| AR090291A1 (es) | 2014-11-05 |
| IL234485A (en) | 2017-02-28 |
| MX2014010584A (es) | 2014-09-18 |
| TW201341385A (zh) | 2013-10-16 |
| KR102085121B1 (ko) | 2020-03-05 |
| US20160024093A1 (en) | 2016-01-28 |
| US8969565B2 (en) | 2015-03-03 |
| AU2013230119B2 (en) | 2017-02-23 |
| UY34669A (es) | 2013-10-31 |
| AU2013230119A1 (en) | 2014-09-25 |
| MX347917B (es) | 2017-05-17 |
| KR20140138865A (ko) | 2014-12-04 |
| CN104470523B (zh) | 2017-07-11 |
| EP2822559B1 (en) | 2018-05-02 |
| NZ630719A (en) | 2017-01-27 |
| WO2013134219A1 (en) | 2013-09-12 |
| JP2015509534A (ja) | 2015-03-30 |
| BR112014022271A2 (OSRAM) | 2017-06-20 |
| EP2822559A1 (en) | 2015-01-14 |
| CA2866164C (en) | 2020-07-07 |
| SG11201405563VA (en) | 2014-10-30 |
| CN104470523A (zh) | 2015-03-25 |
| BR112014022271B1 (pt) | 2021-09-21 |
| US20170057964A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201406148B (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| IL279304A (en) | History of cytotoxic benzodiazepines, preparations containing them and their uses | |
| IL236075A0 (en) | Imidazo [1,2-b] pyridazine kinase inhibitor derivatives, preparations containing them and their uses | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| IL233863A0 (en) | Pyridine derivatives, preparations containing them and their uses | |
| IL228322A0 (en) | History of dispiropyrrolidine, preparations containing them and their uses | |
| AP2014008084A0 (en) | Compositions comprising shortacting benzodiazepines | |
| IL228715A0 (en) | Aminopyrazine compounds, preparations containing them and their uses | |
| EP2619203A4 (en) | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF | |
| PL2600719T3 (pl) | 2-Podstawione 8-alkilo-7-okso-7,8-dihydropirydo[2,3-d]pirymidyno-6-karbonitryle oraz ich zastosowania | |
| ZA201407021B (en) | Novel thienopyrimidine derivatives,processes for the preparation thereof and therapeutic uses thereof | |
| IL233824A (en) | Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use | |
| ZA201404065B (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| IL236712A0 (en) | Di-teri-heteroaryl derivatives, preparations containing them and their uses | |
| IL233825A (en) | H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines | |
| IL232061A (en) | The heterocyclic compound in the bicycle, a pharmaceutical product containing it and its use | |
| IL237542A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL236568A0 (en) | Uses of alkylthiophene-rich compositions and methods of creating these compositions | |
| IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
| PL2851075T3 (pl) | Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu | |
| IL267888B (en) | Amphiphilic compounds, their preparations and uses | |
| IL238461A0 (en) | 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors | |
| IL237540A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL237538A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL237539A0 (en) | Amphiphilic compounds, their preparations and uses |